CO01 | The forkhead box transcription factor foxP3, a prognostic marker for progression-free survival in stage III melanoma Knol AC, Nguyen JM, Khammari A, Quéreux G, Brocard A, Dréno B (France)

 

CO02 | Feasibility and effectiveness of a melanoma targeted screening strategy
Quéreux G, Lequeux Y, Cary M, Jumbou O, Nguyen JM, Dréno B (France)

 

CO03 | Behavioral determinants of successful early melanoma detection
Swetter SM, Pollitt RA, Johnson T, Brooks DR, Geller AC (USA)

 

CO04 | Sun awareness among secondary school students from central Italy
Suppa M, Cazzaniga S, Fargnoli MC, Naldi L, Peris K (Italy)

 

CO05 | Phase I study of the smoothened inhibitor LDE225 in patients with advanced solid tumours: Dose limiting toxicity and anti-tumour activity
Dummer R, Rodon J, Tawbi H, Amakye D, Shou Y, Granvil C, Feng W, Gobbi S, Thomas A, Garcia-Patos V, Mita AC (Switzerland, Spain, USA, United Kingdom)

 

CO06 | Detection rate of sentinel node mapping using combined labeling technique in patients with cutaneous melanoma
Jaukovic L, Rajovic M, Kandolf-Sekulovic L, Novakovic M, Ajdinovic B (Serbia)

 

CO07 | High frequency ultrasonography in the diagnosis of cutaneous pigmented lesions and melanoma reduce the possibilities of diagnostic pitfalls
Szalai K, Hatvani Z, Hársing J, Somlai B, Kárpáti S (Hungary)

 

CO08 | Prognostic value of S-100 protein concentration in the follow up of melanoma: a 12 years experience
Vigato E, Dorizzi RM, Bosco F, Governa M (Italy)

 

CO09 | Determinants of melanoma risk in a large case-control study: the role of skin aging and vitamin D
Suppa M, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, Bakker B, Peris K, Barrett JH, Bishop DT, Newton Bishop JA (United Kingdom, Italy, The Netherlands)

 

CO10 | Importance of duration of high-dose interferon-alfa in the adjuvant therapy of melanoma
Agarwala SS (USA)

 

CO11 | 131I targeted radionuclide therapy by melanin linked molecules for melanoma treatment
Bonnet M, Besse S, Jacquemot N, Communal Y, Papon J, Mishellany F, Cayre A, Penault-Llorca F, Miot-Noirault E, Doly M, Chezal JM, Cluzel J, Moins N, Degoul F (France)

 

CO12 | Chemoablation of metastatic melanoma with intralesional PV-10
Agarwala SS, Thompson JF, Smithers BM, Ross MI, Coventry BJ, Minor DR, Scoggins CR, Wachter EA (Australia, USA)

 

CO13 | Sinonasal mucosal melanomas. About the impact of initial localization and therapeutic modalities on survival: a series of 35 cases
Perret-Court A, Mancini J, Richard MA, Michel J, Monestier S, Giovanni A, Grob JJ (France)

 

CO14 | A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC)
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang ALS, Low JA, Mueller AB, Yauch RL, Reddy JC, Hauschild A (USA)

 

CO15 | The DEPIMELA study: The melanoma/naevus ratio according to dermoscopy method and melanoma risk factors
Tromme I, Sacré L, Hammouch F, Vereecken P, Marot L, Baurain JF, Thomas L, Speybroeck N (Belgium, France)

 

CO16 | The Mitogen Activated Protein Kinase pathway regulates the expression of p18INK4c and p21Waf1/Cip1 cyclin-dependent kinase inhibitors through the activating protein-1 transcription factor
Jalili A, Wagner C, Mertz KD, Pashenkov M, Stingl G, Ramaswamy S, Wagner SN (Austria, Russia, USA)

 

CO17 | Can we further increase benefit for Interferon therapy by selecting patients on certain risk factors
Mohr P (Germany)

 

CO18 | The analytic performance of the cobas® 4800 BRAF V600 Mutation Test in the detection of V600E mutations in malignant melanoma: assay reproducibility and effects of melanin
Kovach B, Langland R, Schilling R, Halait H, Anderson S, Bloom K, Vallera DU, Rueschoff J, Lawrence HJ (USA, Germany)

 

CO19 | Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?
Peuvrel L, Nguyen JM, Khammari A, Quéreux G, Brocard A, Dréno B (France)

 

CO20 | Percutaneous hepatic perfusion (PHP) for metastatic melanoma: Results from a single institution
Zager JS (USA)

 

CO21 | HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome
Sibaud V, Dalenc F, Chevreau C, Roché H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taieb C (France)

 

CO22 | Long term outcomes after interstitial brachytherapy for lower lip carcinoma: a retrospective study of 95 cases
Mervoyer A, Rio E, Bardet E, Malard O, Piot B, Dréno B (France)

 

CO23 | The determinants of periorbital skin aging in a North European population
Suppa M, Elliott F, Mikeljevic JS, Mukasa Y, Chan M, Leake S, Karpavicius B, Haynes S, Bakker B, Peris K, Barrett JH, Bishop DT, Newton Bishop JA (United Kingdom, Italy, The Netherlands)

 

CO24 | Seasonal variations in vitamin D levels in melanoma patients: a single-center prospective pilot comparative study
El Hayderi L, Failla V, Cavalier E, Paurobally D, Chapelle JP, Dezfoulian B, Nikkels AF (Belgium)

 

CO25 | Suberoylanilide hydroxamic acid (Vorinostat) plus Mithramycin A (Plicamycin) treatments in Sézary lymphoma
Bonnet N, Berbis P, Kahn-Perlès B, Costello R (France)

 

CO26 | Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients
Kim YH, Pinter-Brown L, Foss F, Sokol L, Jorgensen JL, Spitalny GL, Duvic M (USA)

 

CO27 | Interest of Cetuximab in the treatment of cutaneous squamous cell carcinoma
Preneau S, Quéreux G, Brocard A, Peuvrel L, Dréno B (France)